Home > Neurology > ECTRIMS 2021 > Biomarkers > Applicability of sNfL measurement in clinical practice

Applicability of sNfL measurement in clinical practice

Presented By
Prof. Elias Sotirchos, Johns Hopkins University, MD, USA
Conference
ECTRIMS 2021
Trial
MS PATHS
Elevated baseline serum neurofilament light (sNfL) levels were associated with longitudinal brain atrophy and the development of new T2 lesions in patients with MS. The results were consistent across demographical and clinical subgroups [1]. First small steps were proposed towards the routine use of sNfL measurements in clinical practice [2]. NfL is a neuronal protein that reflects axonal damage in the cerebrospinal fluid of patients with MS [3]. Serum NfL levels can be used as a marker of drug response and can predict future disease activity in patients with MS [4]. According to Prof. Elias Sotirchos (Johns Hopkins University, MD, USA) there is evidence that sNfL is linked to clinic-radiological measures of inflammatory disease activity. However, assessments of sNfL in large heterogenous MS populations are scarce. The study evaluated the relation between sNfL levels, longitudinal brain atrophy, and new T2 lesion development in patients from the real-world...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on